ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

The Role of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Pediatr…

ISPAD's 50th Annual Conference 2024

A. Sanghavi

Treatment of Hypernatremia

Dr. Mohammed Elhassan

M. Elhassan

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Beyond 10-Year Risk: New Paradigms for Long-Term Risk Estimation Wit…

Heart in Diabetes (HiD)

S. Khan

New Research: Side Effect of GLP1

Susan Brian

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

Is Obesity Management the Next Frontier?

Collaborative CME and Research Network

A. Michael Lincoff

GLP-1 Therapy for Weight Loss

Washington University in St. Louis

K. Jones

EADV 2024 Insights: Calciphylaxis

EADV 2024 Insights

C. Erfurt-Berge

Social Determinants of Health for Cardiovascular Kidney Metabolic Sy…

Kibret Enyew Belay

A New Paradigm: Rethinking Hypherphosphatemia Management

Icahn School of Medicine at Mount Sinai

D. Spiegel

Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists

Ezekiel Emanuel

Choosing the Optimal Blood Pressure Medication for My Hypertensive P…

Rivka Ayalon

Clinical Pearls on How to Prescribe GLP-1 Therapy to Patients with T…

Arelis Madera

FLOW Trial Results: GLPs, the Kidneys, and Even More to Come!!

Robert Busch